Over the years, the nomenclature of this entity has been complicated. It has been alternatively called cranial arteritis or temporal arteritis, reflecting the most commonly affected vessels.

AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg, once ...

The most dramatic symptoms of GCA (for example, visual loss) result directly from the inflammation of the large- and medium-sized cranial vessels ... Giant cell arteritis is a systemic vasculitis ...